Pdl Biopharma Inc (PDLI) 3.27 $PDLI PDL BioPharma to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pdl Biopharma Inc (PDLI) 3.27 $PDLI

PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
PDLI: 3.27 (-0.01)

PDL BioPharma Agrees to Equity Investment in Noden Pharma
Zacks Equity Research - Zacks Investment Research - Wed May 25, 9:02AM CDT
PDL BioPharma (PDLI) announced that it has committed to an equity investment in Noden Pharma to acquire global rights to Tekturna and Tekturna HCT.
PFE: 36.23 (+0.11), BMY: 75.43 (+0.15), PDLI: 3.27 (-0.01), NVS: 82.55 (+0.42)

PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PR Newswire - Tue May 24, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had estimated global sales in 2015 of $154 million. The transactions are expected to close upon Hart-Scott-Rodino regulatory approval or expiration of the related waiting period. PDL's equity investment will ultimately result in an 88% equity interest in Noden. Given this anticipated majority ownership by PDL, the financial statements of Noden will be consolidated with PDL, which is expected to be immediately accretive to PDL's cash earnings.
PDLI: 3.27 (-0.01), NVS: 82.55 (+0.42)

PDL BioPharma Announces First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including:
PDLI: 3.27 (-0.01)

PDL BioPharma Announces 2016 Second Quarter Dividend
PR Newswire - Wed May 04, 3:01PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
PDLI: 3.27 (-0.01)

PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 3.27 (-0.01)

SmarTrend Watching for Potential Pullback in Shares of PDL BioPharma After 6.96% Gain
Comtex SmarTrend(R) - Mon Mar 21, 4:59PM CDT
PDL BioPharma (NASDAQ DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PDLI: 3.27 (-0.01)

Watch for PDL BioPharma to Potentially Pullback After Gaining 6.96% Yesterday
Comtex SmarTrend(R) - Mon Mar 21, 4:58PM CDT
PDL BioPharma (NASDAQ DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PDLI: 3.27 (-0.01)

3 Tempting Stocks to Avoid
Evan Niu, CFA, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 20, 12:00PM CDT
Sometimes it's difficult to distinguish between a value trap and a value buy. Some stocks can look awfully tempting depending on market conditions, and the challenge for investors is to figure out if it's worth taking the plunge.  Here are three...
AMBA: 55.02 (+1.23), GPRO: 11.79 (+0.82), AXP: 61.97 (+0.48), QCOM: 54.36 (+0.17), PDLI: 3.27 (-0.01)

How Patent Risk Poses a Big Threat to PDL BioPharma
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Thu Mar 17, 9:44AM CDT
Developing billion-dollar blockbusters is the Holy Grail of all biotech companies, but investors can be left owning a company that's a fraction of its former self when patents on these drugs expire. Investors in  PDL BioPharma   may be reminded of...
TEVA: 51.10 (+0.21), PDLI: 3.27 (-0.01)

PDL BioPharma Completes Quarterly Dividend Payment
PR Newswire - Mon Mar 14, 5:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date.
PDLI: 3.27 (-0.01)

3 Big Risks Biotech Stocks Face
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Mar 13, 6:22AM CDT
Biotech is a notoriously risky sector. What seems like a sure success one day can easily result in debilitating failure, and companies are constantly making headlines for nosediving in price when expectations fall through. But if you're an investor...
CLDX: 4.66 (+0.02), MNKD: 1.15 (-0.02), PDLI: 3.27 (-0.01)

Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 7.14 (+0.01), XNCR: 18.03 (-0.59), PDLI: 3.27 (-0.01)

Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 7.49 (-0.04), CLVS: 14.60 (-0.13), RLYP: 20.58 (+0.41), PDLI: 3.27 (-0.01)

PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 3.27 (-0.01)

PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 3.27 (-0.01)

PDL BioPharma Announces 2016 First Quarter Dividend
PR Newswire - Mon Feb 01, 3:02PM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
PDLI: 3.27 (-0.01)

3 High-Risk Dividend Stocks I'd Avoid
Andrés Cardenal, Tyler Crowe, and George Budwell, The Motley Fool - Motley Fool - Sat Jan 30, 8:20AM CST
Most investors love dividend stocks, and for good reasons. Statistical studies have proven time and again that investing in companies with strong dividends can be a powerful strategy to achieve superior returns from your portfolio over the long...
PM: 102.75 (-0.34), WMB: 21.06 (+0.07), ETE: 15.79 (+0.21), MO: 69.73 (-0.10), WPZ: 35.93 (+0.23), PDLI: 3.27 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 212

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 238

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 262

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 377

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 192

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading